ArticleMolecular biomedicine2026

Engineered fibroblast growth factor 1 variants uncouple glucose-lowering effects from mitogenic activity with therapeutic potential for type 2 diabetes.

Aleksandra A Czyrek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.